Galapagos NV : Galapagos and Roche conclude strategic alliance

        Galapagos NV : Galapagos and Roche conclude strategic alliance

  oCOPD alliance signed in December 2009 and broadened to fibrosis in
    December 2010
  oStrategic change in therapy area at Roche resulted in conclusion of the
  oGalapagos regains full rights to all programs
  oRoche pays Galapagos €5.75 M for work completed in 2012

Mechelen, Belgium;  8 March  2013 -  Galapagos NV  (Euronext: GLPG)  announced 
today that it agreed with Roche to end their alliance in fibrosis. Roche will
make a  payment of  €5.75 million  to Galapagos  for work  completed in  2012, 
contributing to 2012 Group revenues.

With the ending of the alliance,  Galapagos has regained the worldwide  rights 
to all fibrosis  assays and  the targets  discovered in  the alliance.  These 
novel targets  were identified  in various  unique human  primary cell  assays 
mimicking fibrosis. Galapagos will  have received a total  of €16 million  in 
upfront and milestone payments, including this latest payment.

"We regret that Roche ended  the alliance due to  a strategic change, but  the 
good news is that  all assets have  returned to Galapagos,"  said Onno van  de 
Stolpe, CEO of Galapagos.  "Our plan is to  find another partner to  continue 
the search for compounds against these debilitating diseases."

About Galapagos
Galapagos   (Euronext:   GLPG;   OTC:   GLPYY)   is   specialized   in   novel 
modes-of-action, with a large pipeline of four clinical, six pre-clinical, and
30  discovery  small-molecule  and  antibody  programs  in  cystic   fibrosis, 
inflammation, antibiotics, metabolic disease, and other indications.
GLPG0634 is an orally-available, selective inhibitor of JAK1 for the treatment
of rheumatoid arthritis and potentially other inflammatory diseases, about  to 
enter Phase  2b studies.  AbbVie  and Galapagos  signed a  worldwide  license 
agreement whereby  AbbVie  will be  responsible  for further  development  and 
commercialization after  Phase  2b.  Galapagos  has  another  selective  JAK1 
inhibitor in Phase 2  in lupus and  psoriasis, GSK2586184 (formerly  GLPG0778, 
in-licensed by  GlaxoSmithKline  in  2012).  GLPG0187  is  a  novel  integrin 
receptor antagonist  currently in  a Phase  1b patient  study in  metastasis. 
GLPG0974 is the first  inhibitor of GPR43 to  be evaluated clinically for  the 
treatment of IBD; this program will start a Proof of Concept Phase 2 study  in 
Q2 2013.
The Galapagos Group, including fee-for-service companies BioFocus, Argenta and
Fidelta, has over  800 employees  and operates facilities  in five  countries, 
with global  headquarters  in  Mechelen,  Belgium.  Further  information  at:


Galapagos NV
Onno van de Stolpe, Chief Executive Officer
Tel: +31 6 2909 8028

Elizabeth Goodwin, Director Investor Relations
Tel: +31 6 2291 6240

Galapagos forward-looking statements
This release may contain forward-looking statements, including, without
limitation, statements containing the words "believes," "anticipates,"
"expects," "intends," "plans," "seeks," "estimates," "may," "will," "could,"
"stands to," and "continues," as well as similar expressions. Such
forward-looking statements may involve known and unknown risks, uncertainties
and other factors which might cause the actual results, financial condition,
performance or achievements of Galapagos, or industry results, to be
materially different from any historic or future results, financial
conditions, performance or achievements expressed or implied by such
forward-looking statements. Given these uncertainties, the reader is advised
not to place any undue reliance on such forward-looking statements. These
forward-looking statements speak only as of the date of publication of this
document. Galapagos expressly disclaims any obligation to update any such
forward-looking statements in this document to reflect any change in its
expectations with regard thereto or any change in events, conditions or
circumstances on which any such statement is based, unless required by law or

Galapagos and Roche conclude strategic alliance


This announcement is distributed by Thomson Reuters on behalf of Thomson
Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other
applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of
information contained therein.

Source: Galapagos NV via Thomson Reuters ONE
Press spacebar to pause and continue. Press esc to stop.